Summary
- Oncoclínicas receives a R$1.5 billion capital infusion from issuing new shares, leading to an 18% increase in stock value.
- Key investors include Banco Master and CEO Bruno Lemos Ferrari.
- The funding round aims to support growth strategy and address concerns about high leverage.
- Financial analysts respond positively, projecting future earnings growth and market confidence.
